Memantine Does Not Typically Cause Unilateral Weakness, But Neurologic Worsening Has Been Reported
Memantine is not known to cause isolated left-sided weakness as a typical adverse effect, and this symptom should prompt immediate evaluation for alternative causes such as stroke, particularly given the patient population typically taking this medication.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for memantine lists the most common adverse effects from overdosage and clinical experience as: agitation, asthenia (generalized weakness), bradycardia, confusion, coma, dizziness, ECG changes, increased blood pressure, lethargy, loss of consciousness, psychosis, restlessness, slowed movement, somnolence, stupor, unsteady gait, visual hallucinations, vertigo, vomiting, and weakness 111.
Critically, the weakness described is generalized (asthenia), not unilateral or focal. Unilateral weakness is not listed among the recognized adverse effects in the FDA labeling.
Clinical Trial Safety Data
In high-quality clinical trials evaluating memantine in dementia patients, the documented adverse events included nausea, dizziness, diarrhea, and agitation (withdrawal rates 9-12% in treatment groups vs 7-13% in placebo groups) 222. No focal neurologic deficits or unilateral weakness were reported in these systematic reviews of multiple randomized controlled trials.
Critical Case Reports of Neurologic Worsening
However, there is concerning evidence that memantine can cause worsening of neurologic symptoms in specific populations:
In multiple sclerosis patients, a clinical trial was halted after 7 of 9 patients on memantine (30 mg/day) developed worsening neurologic symptoms including blurred vision, fatigue, severe headache, increased muscle weakness, walking difficulties, and unstable gait 3. These symptoms resolved within days of stopping the medication.
In Lewy body dementia, memantine caused exacerbation of motor and cognitive symptoms, including worsened parkinsonism 4.
Clinical Approach to Left-Sided Weakness
If a patient on memantine develops unilateral left-sided weakness, this is a medical emergency requiring immediate stroke evaluation:
- Do not attribute unilateral weakness to memantine - this is not a recognized adverse effect
- Activate stroke protocol immediately - obtain urgent neuroimaging (CT or MRI brain)
- Assess for stroke mimics - seizure, Todd's paralysis, complicated migraine, hypoglycemia
- Consider the underlying disease - patients on memantine typically have vascular risk factors and dementia, placing them at high stroke risk
If Stroke is Ruled Out
Only after excluding stroke and other serious causes should you consider:
- Medication review - check for drug interactions or recent dose escalation
- Trial discontinuation - if memantine was recently started or dose increased, consider stopping it and monitoring for symptom resolution over 3-5 days
- Neurologic consultation - for persistent unexplained unilateral symptoms
Key Pitfalls to Avoid
- Never dismiss unilateral weakness as a drug side effect without ruling out stroke first
- Do not confuse generalized weakness (asthenia) with focal neurologic deficits
- Be particularly cautious in patients with MS, Lewy body dementia, or Parkinson's disease, where memantine may worsen neurologic symptoms 34
- Remember the patient population - dementia patients on memantine have high baseline stroke risk
The development of unilateral weakness in a patient taking memantine should be treated as a stroke until proven otherwise, not as a medication side effect.